NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief Commercial Officer as the company prepares for anticipated approval of its Abbreviated New Drug Application for a preservative-free ketamine product. Tyson brings more than 25 years of commercialization and sales experience, including senior leadership roles at GSK and Indivior, where he led the successful launch of SUBLOCADE(R), and will oversee the buildout of market access, distribution, sales and marketing capabilities to support upcoming product launches and the company’s broader psychiatry pipeline, including NRX-100 and NRX-101.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer